organic compounds\(\def\hfill{\hskip 5em}\def\hfil{\hskip 3em}\def\eqno#1{\hfil {#1}}\)

Journal logoIUCrDATA
ISSN: 2414-3146

6-Amino-3-methyl-1-phenyl-1H-pyrazolo­[3,4-b]pyrazine-5-carboxamide

CROSSMARK_Color_square_no_text.svg

aDepartment of Chemistry, Keene State College, 229 Main Street, Keene, NH 03435-2001, USA, bChemistry and Environmental Division, Manchester Metropolitan University, Manchester M1 5GD, England, cChemistry Department, Faculty of Science, Minia University, 61519 El-Minia, Egypt, dDepartment of Physics, Faculty of Sciences, Erciyes University, 38039 Kayseri, Turkey, eDepartment of Chemistry, Faculty of Science, Assiut University, 71515 Assiut, Egypt, and fKirkuk University, College of Science, Department of Chemistry, Kirkuk, Iraq
*Correspondence e-mail: shaabankamel@yahoo.com

Edited by E. R. T. Tiekink, Sunway University, Malaysia (Received 30 October 2016; accepted 31 October 2016; online 4 November 2016)

In the title compound, C13H12N6O, the pyrazolo­[3,4-b]pyrazine ring system is planar (r.m.s. deviation for the nine fitted atoms = 0.024 Å) and makes a dihedral angle of 5.72 (6)° with the pendent phenyl ring. The mol­ecular conformation is stabilized by intra­molecular N—H⋯O and C—H⋯N hydrogen bonds, each generating an S(6) loop. In the crystal, pairs of mol­ecules are connected into inversion dimers by strong N—H⋯O hydrogen bonds, forming R22(8) ring motifs. These are linked into sheets parallel to (100) via N—H⋯N hydrogen bonds; ππ inter­actions between symmetry-related pyrazole and phenyl rings [centroid–centroid distances = 3.4453 (9) Å] within the sheets are also noted.

3D view (loading...)
[Scheme 3D1]
Chemical scheme
[Scheme 1]

Structure description

Pyrazole-containing compounds have been shown to exhibit numerous biological activities such as anti-inflammatory (Süküroğlu et al., 2005[Süküroğlu, M., Caliskan Ergün, B., Unlü, S., Sahin, M. F., Küpeli, E., Yesilada, E. & Banoglu, E. (2005). Arch. Pharm. Res. 28, 509-517.]), anti­malarial (Cunico et al., 2006[Cunico, W., Cechinel, C. A., Bonacorso, H. G., Martins, M. A., Zanatta, N., de Souza, M. V., Freitas, I. O., Soares, R. P. & Krettli, A. U. (2006). Bioorg. Med. Chem. Lett. 16, 649-653.]), anti­tumor (Naito, et al., 2002[Naito, H., Ohsuki, S., Sugimori, M., Atsumi, R., Minami, M., Nakamura, Y., Ishii, M., Hirotani, K., Kumazawa, E. & Ejima, A. (2002). Chem. Pharm. Bull. 50, 453-462.]), anti­bacterial, anti­fungal (Akbas et al., 2005[Akbas, E., Berber, I., Sener, A. & Hasanov, B. (2005). Farmaco, 60, 23-26.]; El-Emary, 2006[El-Emary, T. I. (2006). J. Chin. Chem. Soc. 53, 391-401.]), anti­parasitic (El-Kashef et al., 2000[El-Kashef, H. S., El-Emary, T. I., Gasquet, M., Timon-David, P., Maldonaldo, J. & Vanelle, P. (2000). Pharmazie, 55, 572-576.]; Rathelot et al., 2002[Rathelot, P., Azas, N., El-Kashef, H., Delmas, F., Di Giorgio, C., Timon-David, P., Maldonado, J. & Vanelle, P. (2002). Eur. J. Med. Chem. 37, 671-679.]) and anti­viral (Ding et al., 1994[Ding, L., Grehn, L., De Clercq, E., Andrei, G., Snoeck, R., Balzarini, J., Fransson, B., Ragnarsson, U. & Francis, G. W. (1994). Acta Chem. Scand. 48, 498-505.]). This led to the structure determination of the title compound (Fig. 1[link]).

[Figure 1]
Figure 1
The title compound, with 50% probability displacement ellipsoids.

The pyrazolo­[3,4-b]pyrazine ring system of the title compound is essentially planar with puckering parameters Q(2) = 0.0552 (15) Å and φ(2) = 251.1 (15)°. It is inclined to the phenyl ring with a dihedral angle of 5.72 (6)°. The bond lengths and bond angles of the title compound are normal and are in agreement with those reported for a similar compound (Mague et al., 2014[Mague, J. T., Mohamed, S. K., Akkurt, M., El-Emary, T. I. & Albayati, M. R. (2014). Acta Cryst. E70, o1212-o1213.]). Intra­molecular C—H⋯N and N—H⋯O hydrogen bonds form S(6) loop systems (Table 1[link], Fig. 2[link]), stabilizing the mol­ecular conformation.

Table 1
Hydrogen-bond geometry (Å, °)

D—H⋯A D—H H⋯A DA D—H⋯A
N2—H2B⋯O1 0.93 (2) 1.97 (2) 2.6878 (18) 132.1 (17)
C13—H13⋯N3 0.95 2.31 2.985 (2) 127
N1—H1A⋯O1i 0.88 2.07 2.9488 (18) 175
N2—H2A⋯N2ii 0.86 2.50 3.345 (2) 167
Symmetry codes: (i) -x+1, -y+3, -z+1; (ii) [-x+1, y-{\script{1\over 2}}, -z+{\script{3\over 2}}].
[Figure 2]
Figure 2
A view down the b axis of the unit-cell contents of the title compound. Dashed lines indicate hydrogen bonds.

In the crystal, pairs of mol­ecules are connected into inversion dimers by N—H⋯O hydrogen bonds, leading to [R_{2}^{2}](8) ring motifs. These dimers are linked by N—H⋯N hydrogen bonds, leading to the formation of sheets parallel to the bc plane. Further connections within sheets are via ππ inter­actions between symmetry-related pyrazole and phenyl rings [centroid–centroid distances = 3.4453 (9) Å; symmetry operation: x, 1 + y, z].

Synthesis and crystallization

The title compound was prepared according to our reported method (El-Emary, 2007[El-Emary, I. T. (2007). J. Chin. Chem. Soc. 54, 507-518.]). Crystals for X-ray diffraction analysis were obtained by slow evaporation of a dimethyl sulfoxide solution of the compound.

Refinement

Crystal data, data collection and structure refinement details are summarized in Table 2[link].

Table 2
Experimental details

Crystal data
Chemical formula C13H12N6O
Mr 268.29
Crystal system, space group Monoclinic, P21/c
Temperature (K) 173
a, b, c (Å) 14.7907 (5), 4.80351 (15), 17.1203 (8)
β (°) 92.067 (4)
V3) 1215.57 (8)
Z 4
Radiation type Cu Kα
μ (mm−1) 0.83
Crystal size (mm) 0.38 × 0.08 × 0.08
 
Data collection
Diffractometer Rigaku Oxford Diffraction
Absorption correction Multi-scan (CrysAlis PRO; Agilent, 2014[Agilent (2014). CrysAlis PRO. Agilent Technologies Ltd, Yarnton, England.])
Tmin, Tmax 0.909, 1.000
No. of measured, independent and observed [I > 2σ(I)] reflections 4156, 2307, 2011
Rint 0.030
(sin θ/λ)max−1) 0.615
 
Refinement
R[F2 > 2σ(F2)], wR(F2), S 0.041, 0.112, 1.06
No. of reflections 2307
No. of parameters 187
H-atom treatment H atoms treated by a mixture of independent and constrained refinement
Δρmax, Δρmin (e Å−3) 0.22, −0.27
Computer programs: CrysAlis PRO (Agilent, 2014[Agilent (2014). CrysAlis PRO. Agilent Technologies Ltd, Yarnton, England.]), SHELXT (Sheldrick, 2015a[Sheldrick, G. M. (2015a). Acta Cryst. A71, 3-8.]), SHELXL2014 (Sheldrick, 2015b[Sheldrick, G. M. (2015b). Acta Cryst. C71, 3-8.]) and OLEX2 (Dolomanov et al., 2009[Dolomanov, O. V., Bourhis, L. J., Gildea, R. J., Howard, J. A. K. & Puschmann, H. (2009). J. Appl. Cryst. 42, 339-341.]).

Structural data


Computing details top

Data collection: CrysAlis PRO (Agilent, 2014); cell refinement: CrysAlis PRO (Agilent, 2014); data reduction: CrysAlis PRO (Agilent, 2014); program(s) used to solve structure: SHELXT (Sheldrick, 2015a); program(s) used to refine structure: SHELXL2014 (Sheldrick, 2015b); molecular graphics: OLEX2 (Dolomanov et al., 2009); software used to prepare material for publication: OLEX2 (Dolomanov et al., 2009).

6-Amino-3-methyl-1-phenyl-1H-pyrazolo[3,4-b]pyrazine-5-carboxamide top
Crystal data top
C13H12N6OF(000) = 560
Mr = 268.29Dx = 1.466 Mg m3
Monoclinic, P21/cCu Kα radiation, λ = 1.54184 Å
a = 14.7907 (5) ÅCell parameters from 1708 reflections
b = 4.80351 (15) Åθ = 3.9–71.0°
c = 17.1203 (8) ŵ = 0.83 mm1
β = 92.067 (4)°T = 173 K
V = 1215.57 (8) Å3Needle, yellow
Z = 40.38 × 0.08 × 0.08 mm
Data collection top
Rigaku Oxford Diffraction
diffractometer
2307 independent reflections
Radiation source: Enhance (Cu) X-ray Source2011 reflections with I > 2σ(I)
Graphite monochromatorRint = 0.030
Detector resolution: 16.0416 pixels mm-1θmax = 71.4°, θmin = 5.2°
ω scansh = 1318
Absorption correction: multi-scan
(CrysAlis PRO; Agilent, 2014)
k = 53
Tmin = 0.909, Tmax = 1.000l = 1820
4156 measured reflections
Refinement top
Refinement on F2Primary atom site location: structure-invariant direct methods
Least-squares matrix: fullHydrogen site location: mixed
R[F2 > 2σ(F2)] = 0.041H atoms treated by a mixture of independent and constrained refinement
wR(F2) = 0.112 w = 1/[σ2(Fo2) + (0.0562P)2 + 0.3905P]
where P = (Fo2 + 2Fc2)/3
S = 1.06(Δ/σ)max = 0.001
2307 reflectionsΔρmax = 0.22 e Å3
187 parametersΔρmin = 0.27 e Å3
0 restraints
Special details top

Geometry. All esds (except the esd in the dihedral angle between two l.s. planes) are estimated using the full covariance matrix. The cell esds are taken into account individually in the estimation of esds in distances, angles and torsion angles; correlations between esds in cell parameters are only used when they are defined by crystal symmetry. An approximate (isotropic) treatment of cell esds is used for estimating esds involving l.s. planes.

Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å2) top
xyzUiso*/Ueq
O10.49400 (7)1.2243 (2)0.57401 (7)0.0261 (3)
N10.61528 (9)1.3370 (3)0.50430 (8)0.0259 (3)
H1A0.58521.46800.47850.031*
H1B0.67241.30500.49450.031*
N20.51127 (9)0.8234 (3)0.68305 (9)0.0264 (3)
H2A0.49740.68590.71280.032*
N30.64619 (8)0.5919 (3)0.69322 (7)0.0188 (3)
N40.71717 (8)0.9523 (3)0.57703 (7)0.0186 (3)
N50.88003 (8)0.4818 (3)0.66020 (7)0.0203 (3)
N60.80080 (8)0.4173 (3)0.69785 (7)0.0185 (3)
C10.57451 (10)1.1873 (3)0.55802 (9)0.0201 (3)
C20.63173 (10)0.9704 (3)0.59852 (8)0.0187 (3)
C30.59627 (10)0.7917 (3)0.65810 (9)0.0189 (3)
C40.73170 (10)0.5843 (3)0.67103 (8)0.0170 (3)
C50.76778 (10)0.7588 (3)0.61399 (9)0.0182 (3)
C60.86115 (10)0.6839 (3)0.61053 (9)0.0200 (3)
C70.93157 (10)0.8105 (4)0.56164 (10)0.0275 (4)
H7A0.99170.76740.58440.041*
H7B0.92321.01280.55980.041*
H7C0.92610.73460.50850.041*
C80.80259 (10)0.2105 (3)0.75710 (9)0.0188 (3)
C90.88429 (10)0.0839 (3)0.77948 (10)0.0246 (4)
H90.93880.13880.75620.030*
C100.88520 (11)0.1224 (4)0.83593 (10)0.0291 (4)
H100.94080.20870.85120.035*
C110.80605 (12)0.2052 (3)0.87057 (10)0.0281 (4)
H110.80720.34830.90890.034*
C120.72548 (11)0.0761 (3)0.84836 (9)0.0257 (4)
H120.67100.13110.87180.031*
C130.72332 (10)0.1325 (3)0.79237 (9)0.0223 (3)
H130.66780.22180.77820.027*
H2B0.4722 (14)0.939 (4)0.6543 (13)0.036 (5)*
Atomic displacement parameters (Å2) top
U11U22U33U12U13U23
O10.0188 (5)0.0262 (6)0.0333 (6)0.0053 (4)0.0009 (5)0.0035 (5)
N10.0220 (6)0.0268 (7)0.0289 (7)0.0044 (6)0.0004 (5)0.0080 (6)
N20.0169 (6)0.0288 (7)0.0338 (8)0.0048 (6)0.0065 (6)0.0094 (6)
N30.0142 (6)0.0202 (6)0.0219 (6)0.0006 (5)0.0015 (5)0.0010 (5)
N40.0156 (6)0.0200 (6)0.0201 (6)0.0005 (5)0.0004 (5)0.0020 (5)
N50.0135 (6)0.0255 (7)0.0221 (6)0.0001 (5)0.0024 (5)0.0011 (5)
N60.0133 (6)0.0205 (6)0.0216 (6)0.0010 (5)0.0012 (5)0.0010 (5)
C10.0191 (7)0.0182 (7)0.0229 (7)0.0009 (6)0.0021 (6)0.0029 (6)
C20.0171 (7)0.0182 (7)0.0208 (7)0.0000 (6)0.0005 (6)0.0021 (6)
C30.0155 (7)0.0195 (7)0.0218 (7)0.0002 (5)0.0004 (6)0.0034 (6)
C40.0157 (7)0.0175 (7)0.0177 (7)0.0002 (5)0.0006 (5)0.0027 (5)
C50.0151 (7)0.0195 (7)0.0201 (7)0.0003 (5)0.0013 (5)0.0016 (6)
C60.0151 (7)0.0238 (7)0.0212 (7)0.0001 (6)0.0011 (6)0.0012 (6)
C70.0177 (7)0.0356 (9)0.0295 (8)0.0003 (6)0.0049 (6)0.0057 (7)
C80.0185 (7)0.0183 (7)0.0195 (7)0.0008 (6)0.0006 (6)0.0016 (6)
C90.0173 (7)0.0285 (8)0.0280 (8)0.0019 (6)0.0007 (6)0.0017 (7)
C100.0236 (8)0.0312 (8)0.0319 (9)0.0038 (7)0.0052 (7)0.0048 (7)
C110.0335 (9)0.0270 (8)0.0236 (8)0.0014 (7)0.0025 (7)0.0039 (7)
C120.0262 (8)0.0277 (8)0.0235 (8)0.0044 (7)0.0045 (6)0.0007 (6)
C130.0179 (7)0.0243 (7)0.0248 (8)0.0004 (6)0.0016 (6)0.0004 (6)
Geometric parameters (Å, º) top
O1—C11.2444 (18)C4—C51.407 (2)
N1—H1A0.8800C5—C61.430 (2)
N1—H1B0.8800C6—C71.489 (2)
N1—C11.329 (2)C7—H7A0.9800
N2—H2A0.8636C7—H7B0.9800
N2—C31.3509 (19)C7—H7C0.9800
N2—H2B0.93 (2)C8—C91.394 (2)
N3—C31.340 (2)C8—C131.389 (2)
N3—C41.3341 (18)C9—H90.9500
N4—C21.3316 (19)C9—C101.384 (2)
N4—C51.338 (2)C10—H100.9500
N5—N61.3927 (16)C10—C111.389 (2)
N5—C61.314 (2)C11—H110.9500
N6—C41.3656 (19)C11—C121.384 (2)
N6—C81.4193 (19)C12—H120.9500
C1—C21.497 (2)C12—C131.386 (2)
C2—C31.446 (2)C13—H130.9500
H1A—N1—H1B120.0N5—C6—C5110.00 (13)
C1—N1—H1A120.0N5—C6—C7121.93 (13)
C1—N1—H1B120.0C5—C6—C7128.05 (14)
H2A—N2—H2B127.9C6—C7—H7A109.5
C3—N2—H2A110.1C6—C7—H7B109.5
C3—N2—H2B117.8 (13)C6—C7—H7C109.5
C4—N3—C3113.86 (12)H7A—C7—H7B109.5
C2—N4—C5115.77 (12)H7A—C7—H7C109.5
C6—N5—N6107.54 (12)H7B—C7—H7C109.5
N5—N6—C8119.49 (12)C9—C8—N6119.68 (14)
C4—N6—N5110.22 (12)C13—C8—N6120.33 (13)
C4—N6—C8130.23 (13)C13—C8—C9119.98 (14)
O1—C1—N1122.47 (14)C8—C9—H9120.3
O1—C1—C2121.81 (14)C10—C9—C8119.38 (15)
N1—C1—C2115.72 (13)C10—C9—H9120.3
N4—C2—C1116.34 (13)C9—C10—H10119.5
N4—C2—C3121.88 (13)C9—C10—C11121.07 (15)
C3—C2—C1121.78 (13)C11—C10—H10119.5
N2—C3—C2121.43 (13)C10—C11—H11120.5
N3—C3—N2116.29 (13)C12—C11—C10118.98 (15)
N3—C3—C2122.25 (13)C12—C11—H11120.5
N3—C4—N6128.75 (13)C11—C12—H12119.6
N3—C4—C5124.66 (13)C11—C12—C13120.79 (15)
N6—C4—C5106.58 (13)C13—C12—H12119.6
N4—C5—C4121.50 (13)C8—C13—H13120.1
N4—C5—C6132.81 (14)C12—C13—C8119.78 (15)
C4—C5—C6105.66 (13)C12—C13—H13120.1
O1—C1—C2—N4179.29 (13)C2—N4—C5—C40.8 (2)
O1—C1—C2—C30.3 (2)C2—N4—C5—C6176.75 (15)
N1—C1—C2—N40.6 (2)C3—N3—C4—N6176.55 (14)
N1—C1—C2—C3179.82 (13)C3—N3—C4—C52.4 (2)
N3—C4—C5—N40.4 (2)C4—N3—C3—N2174.80 (13)
N3—C4—C5—C6178.55 (13)C4—N3—C3—C23.3 (2)
N4—C2—C3—N2175.69 (14)C4—N6—C8—C9173.91 (14)
N4—C2—C3—N32.3 (2)C4—N6—C8—C136.5 (2)
N4—C5—C6—N5178.32 (15)C4—C5—C6—N50.45 (17)
N4—C5—C6—C70.1 (3)C4—C5—C6—C7177.76 (15)
N5—N6—C4—N3178.54 (13)C5—N4—C2—C1179.62 (12)
N5—N6—C4—C50.58 (16)C5—N4—C2—C30.0 (2)
N5—N6—C8—C93.0 (2)C6—N5—N6—C40.30 (16)
N5—N6—C8—C13176.51 (13)C6—N5—N6—C8177.82 (13)
N6—N5—C6—C50.10 (16)C8—N6—C4—N31.4 (3)
N6—N5—C6—C7178.24 (13)C8—N6—C4—C5177.75 (14)
N6—C4—C5—N4178.78 (13)C8—C9—C10—C110.0 (3)
N6—C4—C5—C60.61 (16)C9—C8—C13—C121.6 (2)
N6—C8—C9—C10178.44 (15)C9—C10—C11—C120.6 (3)
N6—C8—C13—C12177.92 (14)C10—C11—C12—C130.1 (2)
C1—C2—C3—N23.9 (2)C11—C12—C13—C81.0 (2)
C1—C2—C3—N3178.17 (13)C13—C8—C9—C101.1 (2)
Hydrogen-bond geometry (Å, º) top
D—H···AD—HH···AD···AD—H···A
N2—H2B···O10.93 (2)1.97 (2)2.6878 (18)132.1 (17)
C13—H13···N30.952.312.985 (2)127
N1—H1A···O1i0.882.072.9488 (18)175
N2—H2A···N2ii0.862.503.345 (2)167
Symmetry codes: (i) x+1, y+3, z+1; (ii) x+1, y1/2, z+3/2.
 

Acknowledgements

JPJ would like to acknowledge the NSF–MRI program (grant No. CHE-1039027) for funds to purchase the X-ray diffractometer.

References

First citationAgilent (2014). CrysAlis PRO. Agilent Technologies Ltd, Yarnton, England.  Google Scholar
First citationAkbas, E., Berber, I., Sener, A. & Hasanov, B. (2005). Farmaco, 60, 23–26.  CrossRef PubMed CAS Google Scholar
First citationCunico, W., Cechinel, C. A., Bonacorso, H. G., Martins, M. A., Zanatta, N., de Souza, M. V., Freitas, I. O., Soares, R. P. & Krettli, A. U. (2006). Bioorg. Med. Chem. Lett. 16, 649–653.  Web of Science CrossRef PubMed CAS Google Scholar
First citationDing, L., Grehn, L., De Clercq, E., Andrei, G., Snoeck, R., Balzarini, J., Fransson, B., Ragnarsson, U. & Francis, G. W. (1994). Acta Chem. Scand. 48, 498–505.  CrossRef CAS PubMed Google Scholar
First citationDolomanov, O. V., Bourhis, L. J., Gildea, R. J., Howard, J. A. K. & Puschmann, H. (2009). J. Appl. Cryst. 42, 339–341.  Web of Science CrossRef CAS IUCr Journals Google Scholar
First citationEl-Emary, T. I. (2006). J. Chin. Chem. Soc. 53, 391–401.  CAS Google Scholar
First citationEl-Emary, I. T. (2007). J. Chin. Chem. Soc. 54, 507–518.  CAS Google Scholar
First citationEl-Kashef, H. S., El-Emary, T. I., Gasquet, M., Timon-David, P., Maldonaldo, J. & Vanelle, P. (2000). Pharmazie, 55, 572–576.  Web of Science PubMed CAS Google Scholar
First citationMague, J. T., Mohamed, S. K., Akkurt, M., El-Emary, T. I. & Albayati, M. R. (2014). Acta Cryst. E70, o1212–o1213.  CSD CrossRef IUCr Journals Google Scholar
First citationNaito, H., Ohsuki, S., Sugimori, M., Atsumi, R., Minami, M., Nakamura, Y., Ishii, M., Hirotani, K., Kumazawa, E. & Ejima, A. (2002). Chem. Pharm. Bull. 50, 453–462.  Web of Science CrossRef PubMed CAS Google Scholar
First citationRathelot, P., Azas, N., El-Kashef, H., Delmas, F., Di Giorgio, C., Timon-David, P., Maldonado, J. & Vanelle, P. (2002). Eur. J. Med. Chem. 37, 671–679.  Web of Science CrossRef PubMed CAS Google Scholar
First citationSheldrick, G. M. (2015a). Acta Cryst. A71, 3–8.  Web of Science CrossRef IUCr Journals Google Scholar
First citationSheldrick, G. M. (2015b). Acta Cryst. C71, 3–8.  Web of Science CrossRef IUCr Journals Google Scholar
First citationSüküroğlu, M., Caliskan Ergün, B., Unlü, S., Sahin, M. F., Küpeli, E., Yesilada, E. & Banoglu, E. (2005). Arch. Pharm. Res. 28, 509–517.  Web of Science PubMed Google Scholar

This is an open-access article distributed under the terms of the Creative Commons Attribution (CC-BY) Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original authors and source are cited.

Journal logoIUCrDATA
ISSN: 2414-3146
Follow IUCr Journals
Sign up for e-alerts
Follow IUCr on Twitter
Follow us on facebook
Sign up for RSS feeds